Jul. 30 at 10:53 PM
$CRVO unbelievable news and it's bleeding still
BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial showing that oral neflamapimod continued to demonstrate slowing of disease progression and demonstrated an effect on a plasma marker of neurodegeneration in patients with DLB. The disease progression analyses were featured in two presentations during the Alzheimer’s Association® International Congress 2025 (AAIC) on Sunday, July 27th, 2025.
“We are thrilled by these unprecedented data demonstrating a 54% reduction in risk of clinically significant worsening on the CDR-SB over 32 weeks of treatment, improving to 64% when applying the more stringent ptau181 threshold to define DLB without Alzheimer’s Disease (AD) co-pathology –
